|
|
|
| Application of serum PAPP-A, PLGF and ADAM12 detection in prenatal screening of Down's syndrome during the first trimester of pregnancy |
| The Fourth People's Hospital of Haikou, Hainan Province, 571100 |
|
|
|
|
Abstract To study the effect of serum pregnancy associated protein A (PAPP-A), human placental growth factor (PLGF), and deintegrin metalloproteinase-12 (ADAM12) detection in prenatal screening of Down's syndrome during the first trimester of pregnancy. Methods: A retrospective study was conducted in this study. 110 pregnant women with Down syndrome fetus by Down's screening from December 2017 to December 2019 were selected in research group, and 110 normal pregnant women were selected in control group during the same period. The serum PAPP-A, PLGF and ADAM12 levels of the women were compared between the two groups. And the diagnostic efficiency of serum PAPP-A, PLGF and ADAM12 levels for Down's syndrome was analyzed. Results: The serum levels of PAPP-A (0.14±0.03 mIU/ml), PLGF (64.31±12.95 pg/ml), and ADAM12 (789.43±101.33μg/L) of the women in the research group were significant lower than those of the women in the control group (P＜0.05). The sensitivity of the combinational serum PAPP-A, PLGF and ADAM12 levels of the women for Down's syndrome in the research group was the highest (81.8%), and their area under ROC curve was the highest (0.654-0.912). The cut-off value of serum PAPP-A level, PLGF level, or ADAM12 level for diagnosing Down's syndrome were 0.13 mIU/mL, 64.23 pg/mL, and 788.64μg/L, respectively. Conclusion: The combinational serum PAPP-A, PLGF and ADAM12 levels of the women for diagnosing Down's syndrome in prenatal screening during the first trimester of pregnancy has significant value, which can improve the diagnostic sensitivity of Down's syndrome.
|
|
|
|
|
|
|
|
|
